Accelerating Pharmaceutical Innovation with AI
RISE develops AI methods that predict safety-associated risks in early drug structure design, enabling pharmaceutical companies to advance drug candidates to clinical trials in under a year.
AI is transforming research, notably in pharmaceuticals, where new drugs now reach clinical trials in under a year, much faster than the previous 3-4 years.
RISE’s Contribution
RISE develops AI methods that predict safety-associated risks in early structure design, aiding pharmaceutical companies in quickly and accurately advancing drug candidates to regulatory tests for human trials.
Capabilities
These methods excel in sifting through thousands of potential candidates, expediting the delivery of new medicines to patients.
Broader Applications
These innovations are also applied in the Mistra Safechem program, where RISE collaborates with the chemical industry on safe, sustainable processes.
Impact
By identifying potential safety issues earlier in the drug development process, AI helps reduce the time and cost of bringing new treatments to patients while improving the likelihood of success in clinical trials.
